JP7311489B2 - 異種ｒｅｐＲＮＡ免疫化のための方法および組成物 - Google Patents

異種ｒｅｐＲＮＡ免疫化のための方法および組成物 Download PDF

Info

Publication number
JP7311489B2
JP7311489B2 JP2020504146A JP2020504146A JP7311489B2 JP 7311489 B2 JP7311489 B2 JP 7311489B2 JP 2020504146 A JP2020504146 A JP 2020504146A JP 2020504146 A JP2020504146 A JP 2020504146A JP 7311489 B2 JP7311489 B2 JP 7311489B2
Authority
JP
Japan
Prior art keywords
composition
reprna
ivt
antigenic
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020504146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528911A5 (https=
JP2020528911A (ja
Inventor
ヴォゲルス，ロナルド
デル ヌー コルフショーテン，マライン ヴァン
ジェィ． アーヴァイン，ダレル
ウェイス，ロン
ブラントン ポーター，イーリー
バンデイラ メロ，マリアンヌ
キタダ，タスク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Janssen Vaccines and Prevention BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines and Prevention BV filed Critical Janssen Vaccines and Prevention BV
Publication of JP2020528911A publication Critical patent/JP2020528911A/ja
Publication of JP2020528911A5 publication Critical patent/JP2020528911A5/ja
Application granted granted Critical
Publication of JP7311489B2 publication Critical patent/JP7311489B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020504146A 2017-07-28 2018-07-27 異種ｒｅｐＲＮＡ免疫化のための方法および組成物 Active JP7311489B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762538070P 2017-07-28 2017-07-28
US62/538,070 2017-07-28
US201762546259P 2017-08-16 2017-08-16
US62/546,259 2017-08-16
PCT/US2018/044075 WO2019023566A1 (en) 2017-07-28 2018-07-27 METHODS AND COMPOSITIONS FOR PROVIDING IMMUNIZATION AGAINST Heterologous ARNREP

Publications (3)

Publication Number Publication Date
JP2020528911A JP2020528911A (ja) 2020-10-01
JP2020528911A5 JP2020528911A5 (https=) 2021-08-26
JP7311489B2 true JP7311489B2 (ja) 2023-07-19

Family

ID=63407511

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020504146A Active JP7311489B2 (ja) 2017-07-28 2018-07-27 異種ｒｅｐＲＮＡ免疫化のための方法および組成物

Country Status (12)

Country Link
US (2) US11235051B2 (https=)
EP (1) EP3658179B1 (https=)
JP (1) JP7311489B2 (https=)
KR (1) KR102806640B1 (https=)
CN (1) CN111163799A (https=)
AU (1) AU2018306614B2 (https=)
BR (1) BR112020001052A2 (https=)
CA (1) CA3071011A1 (https=)
IL (1) IL272281B2 (https=)
MA (1) MA49693A (https=)
SG (1) SG11202000019RA (https=)
WO (1) WO2019023566A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021010611A2 (pt) * 2018-12-14 2021-08-24 Glaxosmithkline Biologicals S.A. Composições e métodos de vacina de reforço (prime boost) heterólogo
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2020146700A1 (en) * 2019-01-10 2020-07-16 Massachusetts Institute Of Technology Lipid nanoparticles
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
AU2021236068A1 (en) * 2020-03-09 2022-10-06 Arcturus Therapeutics, Inc. Compositions and methods for inducing immune responses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4196128A4 (en) 2020-08-14 2024-06-12 Arcturus Therapeutics, Inc. METHOD FOR FREEZE DILIZATION OF LIPID NANOPARTICLES
JP2024509769A (ja) 2021-02-23 2024-03-05 ヤンセン ファッシンズ アンド プリベンション ベーフェー 三量体安定化ｈｉｖエンベロープタンパク質変異
US20240301385A1 (en) 2021-03-22 2024-09-12 LifeEDIT Therapeutics, Inc. Dna modifying enzymes and active fragments and variants thereof and methods of use
CN115232824B (zh) * 2021-04-22 2023-09-26 中国人民解放军军事科学院军事医学研究院 一种基于1083骨架的预防狂犬病毒感染的疫苗
US20240400619A1 (en) * 2021-09-02 2024-12-05 Replicate Bioscience, Inc. Modified alphaviruses with heterologous nonstructural proteins
WO2023156505A1 (en) 2022-02-17 2023-08-24 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l
CN119317430A (zh) * 2022-04-26 2025-01-14 斯特兰德生物科技公司 包含委内瑞拉马脑炎(vee)复制子的脂质纳米颗粒及其用途
CN116064597B (zh) * 2023-01-17 2024-04-26 北京大学 通过自主复制rna实现哺乳动物细胞中的定向进化和达尔文适应

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046621A2 (en) 2003-11-12 2005-05-26 The United States Of America As Represented By The Secretary Of The Navy Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
US20140271714A1 (en) 2013-03-15 2014-09-18 Monika Simmons Induction of an immune response against dengue virus using the prime-boost approach

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
WO2003104467A1 (en) 2002-04-25 2003-12-18 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
EP1497440B1 (en) 2002-04-25 2008-08-20 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
DE602005017743D1 (de) 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
EP2146760B1 (en) 2007-04-30 2018-10-10 Medtronic MiniMed, Inc. Reservoir filling, bubble management, and infusion medium delivery systems and methods with same
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
PL2391638T3 (pl) 2009-02-02 2018-11-30 Glaxosmithkline Biologicals Sa Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania
CA2766907A1 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
CA2768186A1 (en) * 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
MX342608B (es) 2010-07-06 2016-10-06 Novartis Ag * Particulas de suministro similares a viriones para moleculas de arn de autorreplicacion.
DK2655604T3 (en) * 2010-12-14 2018-08-06 Us Gov Health & Human Services ADENOVIRUS SEROTYPE-26- AND SEROTYPE-35-FILOVIRUS VACCINES
EA027236B1 (ru) * 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
CA2841047A1 (en) * 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
CA2878344A1 (en) 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins
CA2960096A1 (en) * 2014-09-03 2016-03-10 Bavarian Nordic A/S Methods and compositions for enhancing immune responses
BE1023877B1 (fr) * 2015-05-21 2017-09-01 Glaxosmithkline Biologicals Sa Procédés et compositions pour l’induction d’une immunité protectrice contre une maladie et/ou une infection à filovirus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046621A2 (en) 2003-11-12 2005-05-26 The United States Of America As Represented By The Secretary Of The Navy Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
US20140271714A1 (en) 2013-03-15 2014-09-18 Monika Simmons Induction of an immune response against dengue virus using the prime-boost approach

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
INFECTION AND IMMUNITY, 2003, Vol. 71, No. 3, p.1491-1496
JOURNAL OF VIROLOGY, 2011, Vol.85, No.9, pp.4222-4233
Vaccine, 2008, Vol.26, pp.6108-6118

Also Published As

Publication number Publication date
EP3658179C0 (en) 2025-09-17
EP3658179A1 (en) 2020-06-03
CN111163799A (zh) 2020-05-15
MA49693A (fr) 2020-06-03
US20220111033A1 (en) 2022-04-14
AU2018306614A1 (en) 2020-01-30
US11964007B2 (en) 2024-04-23
SG11202000019RA (en) 2020-02-27
IL272281B2 (en) 2023-04-01
KR20200037818A (ko) 2020-04-09
CA3071011A1 (en) 2019-01-31
JP2020528911A (ja) 2020-10-01
US20200230225A1 (en) 2020-07-23
IL272281A (en) 2020-03-31
US11235051B2 (en) 2022-02-01
IL272281B (en) 2022-12-01
EP3658179B1 (en) 2025-09-17
KR102806640B1 (ko) 2025-05-12
AU2018306614B2 (en) 2024-08-29
BR112020001052A2 (pt) 2020-09-08
WO2019023566A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
JP7311489B2 (ja) 異種ｒｅｐＲＮＡ免疫化のための方法および組成物
AU2003297039B2 (en) Multi-antigenic alphavirus replicon particles and methods
Ljungberg et al. Self-replicating alphavirus RNA vaccines
Capone et al. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials
Vajdy et al. Mucosal adjuvants and delivery systems for protein‐, DNA‐and RNA‐based vaccines
US20220062409A1 (en) Heterologous prime boost vaccine compositions and methods
US11229692B2 (en) Methods and compositions for inducing protective immunity against RSV infection
JP2019123734A (ja) 免疫応答の増進を目的とする方法及び組成物
JP2017048207A (ja) アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン
AU2017297610A1 (en) Compositions and methods for alphavirus vaccination
Russell et al. Frontrunners in the race to develop a SARS-CoV-2 vaccine
Chang et al. Polyplex nanomicelle delivery of self-amplifying RNA vaccine
JP2020511145A (ja) 改良されたｌｉワクチンアジュバント
HK40031089A (en) Methods and compositions for heterologous reprna immunizations
HK40031089B (en) Methods and compositions for heterologous reprna immunizations
EA043316B1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ГЕТЕРОЛОГИЧНЫХ репРНК ИММУНИЗАЦИЙ
JP2022551107A (ja) アデノウイルスベクターおよびその使用
Matthews et al. 210. A Comparative Study of Non-Integrating and Integrating Lentiviral Vectors in Eliciting an Effective Immune Response Against Hepatitis B Surface Antigen in Mice

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230510

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230517

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230620

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230706

R150 Certificate of patent or registration of utility model

Ref document number: 7311489

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150